Exploring the Association of Imaging and Tumor Microenvironment in Urologic Cancer Using Radiogenomic Approach（Radiogenomics-Urinary）

Launched by WUHAN UNION HOSPITAL, CHINA · Jul 31, 2024

Keywords

ClinConnect Summary

This clinical trial, called "Radiogenomics-Urinary," is studying how imaging tests like CT scans and MRIs relate to the tumor environment in patients with urologic cancers, such as bladder or prostate cancer. The goal is to understand how these factors might predict a patient's outcomes and overall prognosis. The study is currently recruiting participants who have been treated for urologic cancer at Wuhan Union Hospital between August 2024 and August 2027. To be eligible, participants must be over 18 years old, have had at least one imaging test before treatment, and have a confirmed diagnosis through a tissue biopsy.

Participants in this study can expect to provide information about their imaging tests and medical history, which will help researchers learn more about the disease. It's important to note that patients with poor-quality images, incomplete medical data, another type of cancer, or unclear diagnoses may not qualify for this trial. Overall, this research aims to improve our understanding of urologic cancers and may help doctors provide better care in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients treated for urologic cancer in Wuhan Union Hospital from August 2024 to August 2027;
• • 2. Aged \> 18 years old;
• • 3. At least one CT scan or MRI scan before treatment;
• • 4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.
• • Exclusion criteria：
• • 1. Poor image quality;
• • 2. Incomplete clinical data or loss of follow-up;
• • 3. Presence of another primary malignancy other than urologic cancer;
• • 4. Unclear pathological diagnosis。